Relmada Therapeutics, Inc. · NASDAQ:RLMD

Relmada Therapeutics — Investor Presentation (March 2026)

40 slides from Relmada Therapeutics's investor presentation, Mar 20, 2026

  1. Slide 1: Corporate Overview: Unlocking Life Changing Therapies

    Exhibit 99.2 C O R P O R A T E O V E R V I E W Unlocking Life Changing Therapies March 2026

  2. Slide 2: Disclosures

    Disclosures The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf. This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933

  3. Slide 3: Investment Thesis

    Investment Thesis Innovative pipeline of potential high - value assets , led by NDV - 01 for non - muscle invasive bladder cancer (NMIBC) NDV - 01, a late - stage sustained - release Gem/Doce with attractive commercial profile and well - defined regulatory pathway Improvement vs. conventional Gem/Do

  4. Slide 4: Innovative Pipeline of Potential High-Value Assets

    Innovative Pipeline of Potential High - Value Assets Focused on programs with positive proof - of - concept data Candidate / Indication Phase 1 Phase 2 Phase 3 Status / Potential Next Steps NDV - 01 1 High - Risk NMIBC (Study TRCG - 001) 2026 : Present data at upcoming medical meetings, continue enr

  5. Slide 5: Sustained-release intravesical formulation of gemcitabine/docetaxel for NMIBC

    NDV - 01 A sustained - release intravesical formulation of gemcitabine/docetaxel (Gem/Doce) for patients with NMIBC, with positive Phase 2a data 1 1. Relmada press release March 9, 2025 NMIBC: Non - muscle invasive bladder cancer. The graphic is for artistic purposes only, not a factual representati

  6. Slide 6: Our Focus: Non-Muscle Invasive Bladder Cancer (NMIBC)

    Our Focus: Non - Muscle Invasive Bladder Cancer (NMIBC) 80% 20% of new cases 1,2 of new cases 1,2 Non - muscle invasive Muscle - invasive NMIBC MIBC • Tumors have invaded bladder muscle with or • Papillary tumors: non - invasive without lymph node involvement projections from the bladder surface • T

  7. Slide 7: NMIBC Represents Multi-Billion Dollar Market Opportunity

    NMIBC Represents Multi - Billion Dollar Market Opportunity US prevalence of Bladder Cancer 1 (Overall Bladder Cancer ) New bladder cancer cases 2 71 - 97% 5 - year overall survival, 8% with advanced disease 3 ~744,000 ~85,000 Key Highlights High incidence 1 4.2% of all new cancer cases in the US Hig

  8. Slide 8: NMIBC Patient Journey

    NMIBC Patient Journey (*) Initial NDV - 01 Registrational Pathways Risked - Based Therapies 4 Adjuvant therapy (chemotherapy, immunotherapy, systemic therapy) based on patients risk category. Symptoms 1 Patient presents to Low - Risk Intermediate - Risk High - Risk BCG - Unresponsive physician; most

  9. Slide 9: Overview of NMIBC Treatment Landscape

    Overview of NMIBC Treatment Landscape Approved and emerging treatments TURBT Surgery Intravesical Chemotherapy Gene Therapy/ Immunotherapy Systemic Therapy Complications (>15%) 1 Emerging dataset Risk of recurrence (50 - 80%) 2 Supply issues Risk of recurrence OR procedure under anesthesia Conventio

  10. Slide 10: The Burden of Recurrences and TURBT is High

    The Burden of Recurrences and TURBT is High Frequent recurrences for IR NMIBC patients: ~ 1 recurrence / year 1 Recurrences typically require TURBT Invasive OR procedure with anesthesia • Complication rate > 15% 2 • 5 - year risk of initial recurrence: 54.4%. After initial recurrence 60.1% of patien

  11. Slide 11: Gem/Doce Combination Stands Out in Urology Times Survey

    Gem/Doce Combination Stands Out in Urology Times Survey 1 What is your preferred treatment for patients with BCG - unresponsive NMIBC? When selecting intravesical therapy after BCG - unresponsive NMIBC, which agent do you most commonly use? Gemcitabine plus docetaxel (Gem/Doce) Intravesical chemothe

  12. Slide 12: Significant Issues with Conventional Gem/Doce Intravesical Therapy for NMIBC

    Significant Issues with Conventional Gem/Doce Intravesical Therapy for NMIBC Preparation by specialized pharmacy First administration 4 - hour total procedure time vs. <5 minutes for NDV - 01 Requires specialized pharmacy preparation vs. NDV - 01 comes ready for use in two pre - filled plastic syrin

  13. Slide 13: Targeted Sustained-Release Intravesical Gem/Doce

    NDV - 01 - Targeted Sustained - Release Intravesical Gem/Doce Bladder - targeted solid matrix enables prolonged tumor exposure to the cytotoxic drug combination via multiple delivery modalities Diffusion through pores Diffusion through the polymer Osmotic pumping Erosion ©2026 Relmada - All rights r

  14. Slide 14: In-vitro Drug Concentrations Show Continuous & Optimized Drug Release

    NDV - 01 in - vitro Drug Concentrations Show Continuous & Optimized Drug Release NDV - 01 Gem/Doce Concentration Over Time NDV - 01 Cumulative Release Profile 3000 30 25 20 15 10 5 100 90 80 70 60 50 40 30 20 10 Gem, µg/ml DCTX, µg/ml 2500 2000 1500 1000 500 0 Gemcitabine Release % Docetaxel Release

  15. Slide 15: Clinically De-Risked with Clear Competitive Advantages

    NDV - 01: Clinically De - Risked with Clear Competitive Advantages Ready for Use: Rapid, Office - Based Administration NDV - 01 comes as two prefilled syringes instilled in < 5 minutes Convenience: Unlocks Community - Based Treatment In - office administration by MA/RN/LPN without specialized infusi

  16. Slide 16: Study TRCG-001 for High-Risk NMIBC

    Study TRCG - 011 for High - Risk NMIBC An open - label, single - arm, single - center Phase 2a study to evaluate safety and efficacy of NDV - 01 in HR NMIBC patients (NCT06663137) HR: High Risk; NMIBC: Non - muscle invasive bladder cancer ©2026 Relmada - All rights reserved 16

  17. Slide 17: Ongoing TRCG-001 Study Design

    ONGOING TRCG - 011 STUDY Study Design Inclusion Criteria Primary Endpoint Secondary Endpoint Exploratory Purpose • High - risk disease with Evaluate the potential of NDV - 01 as a safe and effective treatment for patients with high - risk NMIBC • Safety • DOR • PK CIS, Ta/T 1 tumors 1, 2 • CR Rate a

  18. Slide 18: Ongoing TRCG-001 Study Demographic Data

    ONGOING TRCG - 011 STUDY Demographic Data Characteristics N=48 % Age Median (range) Sex 75 (52 - 93) yr Male 42 6 87.5% 12.5% Female BCG doses Median BCG doses (range) BCG - status BCG - naive BCG - exposed BCG - unresponsive Stage 9 (3 - 23) 23 5 47.9% 10.4% 41.7% 20 CIS +/ - Ta/T1 Ta HG 12 29 7 25

  19. Slide 19: Provided Durable Response Over Time

    ONGOING TRCG - 011 STUDY NDV - 01 Provided Durable Response Over Time Patient # Stage BCG status 3 months 6 months 9 months 12 months 01 - 002 01 - 007 01 - 009 01 - 010 01 - 011 CIS T1 T1 T1 T1+CIS Ta Ta Ta Ta Ta Ta Ta Ta Ta Ta CIS Ta BCG - UR BCG - exposed BCG - UR BCG - naive BCG - naive BCG - ex

  20. Slide 20: Efficacy and Tolerability

    ONGOING TRCG - 011 STUDY Efficacy and Tolerability Efficacy Evaluable Patients 1 (Complete Response) BCG - UR Subpopulation (Complete Response) n/N 36/38 33/38 25/29 22/26 19/25 - % n/N 16/17 14/17 12/14 10/11 8/10 - % Anytime 95% 87% 86% 85%* 76%* 83% Anytime 94% 82% 86% 91% 80% 84% 3 - month 3 - m

  21. Slide 21: Treatment-Related AE and Tolerability

    ONGOING TRCG - 011 STUDY Treatment - Related AE and Tolerability No patient had ≥ Grade 3 TRAE No patients discontinued treatment due to AEs Of the 48 patients who received ≥ 1 dose of NDV - 01, 30 (63%) had a TRAE • 54% transient uncomfortable urination (dysuria) • 8% asymptomatic positive urine cu

  22. Slide 22: The Presence of CIS Does NOT Impact Gem/Doce RFS

    BCG - Unresponsive NMIBC: The Presence of CIS Does NOT Impact Gem/Doce RFS 1 Steinberg et al. (2020): n=276; heavily - pre - treated with BCG 12 - month RFS: • Any CIS = 60% • HG papillary alone = 61% Cox regression analysis for risk factors: • Presence of CIS does NOT Impact RFS (p=0.15) 1. As demo

  23. Slide 23: RESCUE Phase 3 Program

    Phase 3 Program R ecurrent / E ndovesical / S urgery - sparing / C ombination therapy for / U rothelial cancer / E ffectiveness ©2026 Relmada - All rights reserved 23

  24. Slide 24: RESCUE Trial: Two Independent Approval Pathways

    PHASE 3 RESCUE TRIAL Two Independent NDV - 01 Approval Pathways Provide Significant Market Opportunity Registrational Pathway 2 Registrational Pathway 1 Open label randomized controlled trial in intermediate - risk NMIBC – adjuvant therapy following TURBT (NDV - 01 vs. observation) Single - arm tria

  25. Slide 25: RESCUE Trial Cohort 2A: 2L BCG-Unresponsive NMIBC

    PHASE 3 RESCUE TRIAL Cohort 2A: 2L BCG - Unresponsive NMIBC Open - label, single - arm study to evaluate safety and efficacy of NDV - 01 in BCG - UR refractory to first - line therapy Inclusion Criteria Purpose Primary Endpoint Secondary Endpoint Other • HR BCG - UR with CIS refractory to first - li

  26. Slide 26: RESCUE Trial Cohort 1: Adjuvant Intermediate-Risk NMIBC

    PHASE 3 RESCUE TRIAL Cohort 1: Adjuvant Intermediate - Risk NMIBC Registrational Randomized study of TURBT + NDV - 01 vs. TURBT in IR NMIBC Inclusion Criteria Primary Endpoint Secondary Endpoint • IR NMIBC DFS* • HG - RFS • PFS • • • IBCG risk factors ≥ 1 Safety • QOL Study design Intravesical NDV -

  27. Slide 27: Expecting to Advance Towards Registration-Track Studies in Mid-2026

    Expecting to Advance NDV - 01 Towards Registration - Track Studies in Mid - 2026 Initiate Phase 3 RESCUE Trials Target two independent registrational pathways: • 2L BCG - Unresponsive NMIBC patients Mid 2026 • Adjuvant Intermediate - Risk NMIBC patients Interim Phase 3 2L BCG - Unresponsive 3 - mont

  28. Slide 28: Sepranolone

    Sepranolone A novel candidate, with potential to overcome the challenges of current therapies for compulsivity disorders ©2026 Relmada - All rights reserved 28

  29. Slide 29: Sepranolone Has the Potential to Normalize GABA A Receptor Activity

    Sepranolone Has the Potential to Normalize GABA A Receptor Activity GABA ( Υ - aminobutyric acid) is the primary neurotransmitter, involved in anxiety and compulsive disorders 1,2 In some individuals, ALLO exacerbates anxiety and Sepranolone Allopregnanolone normalizes GABA A receptor activity witho

  30. Slide 30: Positive Phase Data and Unique MOA Give Sepranolone Broad Potential

    Positive Phase 2 Data and Unique MOA Give Sepranolone Broad Potential Neurological disorder characterized by repetitive, involuntary tics, with childhood onset Genetic disorder often defined by persistent hunger and overeating Prader - Willi Syndrome Tourette Syndrome Global prevalence 350 - 400K pe

  31. Slide 31: Sepranolone: Highlights & Development Value

    Sepranolone: Highlights & Development Value Differentiated therapeutic candidate for compulsivity - related disorders, supported by positive proof - of - concept data in Tourette’s syndrome Phase 2 study in Prader - Willi syndrome (PWS) planned for H1 2026, targeting a rare genetic disorder affectin

  32. Slide 32: Expecting to Advance Sepranolone Towards Phase 2 Study in Prader-Willi Syndrome

    Expecting to Advance Sepranolone Towards Phase 2 Study in Prader - Willi Syndrome in Mid - 2026 Mid 2026 Initiation of Pilot Phase 2 study in Prader - Willi Syndrome Focus on evaluating early proof - of - concept PWS: Prader - Willi syndrome ©2026 Relmada - All rights reserved 32

  33. Slide 33: Corporate Summary

    Corporate Summary ©2026 Relmada - All rights reserved 33

  34. Slide 34: Financial Overview

    Financial Overview $160 million PIPE 2 $93.0 million ~104.8 million 3 1 Cash, cash Gross proceeds from PIPE Common equivalents & short - term investments shares outstanding (net ~$150M million) ~127.9 million as converted – includes 15M outstanding options (weighted average exercise price of $12.51/

  35. Slide 35: Thank You!

    B Thank You!

  36. Slide 36: Appendix

    Appendix

  37. Slide 37: Gem/Doce combination has been embraced by the urologic oncology community

    Gem/Doce combination has been embraced by the urologic oncology community Effective salvage treatment for patients who have failed or are intolerant to BCG with reported 2 - year RFS ~50% 1, 2, 3 Gem/Doce is an effective alternative first - line agent in high - risk BCG naïve patients with 2 - year

  38. Slide 38: RESCUE Trial Cohort 2B: 2L BCG-Unresponsive NMIBC

    PHASE 3 RESCUE TRIAL Cohort 2B: 2L BCG - Unresponsive NMIBC Open - label, single - arm study to evaluate safety and efficacy of NDV - 01 in BCG - UR refractory to first - line therapy Inclusion Criteria Purpose Primary Endpoint Secondary Endpoint Other • HR BCG - UR papillary only refractory to • Sa

  39. Slide 39: Sepranolone Has the Potential to Normalize GABA A Receptor Activity

    Sepranolone Has the Potential to Normalize GABA A Receptor Activity PAM GABA https://asarinapharma.com/sepranolone/how - does - sepranolone - work/ ©2026 Relmada - All rights reserved 39

  40. Slide 40: Management Leadership and Board of Directors

    Management Leadership Board of Directors Sergio Traversa Maged Shenouda Chuck Ence Chief Accounting and Charles J. Casamento John Glasspool Fabiana Fedeli Chief Executive Officer Chief Financial Officer Chairman of the Board Director Director Compliance Officer Paul Kelly Chief Operating Officer Raj

Relmada Therapeutics — Investor Presentation (March 2026) on 6ix